New challenges in perioperative management of pancreatic cancer

doi:10.3748/wjg.v21.i8.2281

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 21, Issue 8

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (11857)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

695

WORD

323

HTML

5374

Figures (1-2)

281

Tables (1-4)

292

Sum=6965

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

1048

Download

1120

Sum=2168

Publishing Process of This Article

Item

Count

Browse

1088

Download

1636

Sum=2724

Feb 28, 2015 (publication date) through Feb 9, 2025

Times Cited of This Article

Times Cited (49)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Feb 28, 2015; 21(8): 2281-2293
Published online Feb 28, 2015. doi: 10.3748/wjg.v21.i8.2281

Table 3 Major phase III ongoing adjuvant/neoadjuvant trials

Sponsor/study name	Treatment arms	Primary outcome	Clinicaltrial.gov No.	EudraCT number
Unicancer	Gemcitabine vs folfirinox	DFS	NCT01526135
Celgene corporation	Nab-paclitaxel + gem vs gem	OS	NCT01964430
Radiation therapy Oncology group	Pre and post CRT 5-FU vs pre and post CRT gem	OS, DFS	NCT00003216
National cancer institute	Gem vs gem + erlotinib, followed by CT vs CRT with capecitabine or 5-FU	OS	NCT01013649
EORTC trial 40084 - 22084	Gem vs gem + erlotinib followed or not by CRT with capecitabine or 5-FU	OS		2011-000618-20
CONKO 005	Gem vs gem + erlotinib	DFS		2007-003813-15

FOLFIRINOX: 5-Fluorouracil, folinic acid, irinotecan and oxaliplatin; 5-FU: 5-Fluorouracil; FA: Folinic acid; Gem: Gemcitabine; OS: Overall survival; DFS: Disease free survival.

Citation: Puleo F, Maréchal R, Demetter P, Bali MA, Calomme A, Closset J, Bachet JB, Deviere J, Laethem JLV. New challenges in perioperative management of pancreatic cancer. World J Gastroenterol 2015; 21(8): 2281-2293
URL: https://www.wjgnet.com/1007-9327/full/v21/i8/2281.htm
DOI: https://dx.doi.org/10.3748/wjg.v21.i8.2281